In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA ...
With the FDA nod, Alecensa becomes the second molecularly targeted therapy to move into the adjuvant setting for non-small cell lung cancer.
The Food and Drug Administration is signing off on a first prescription digital treatment to help with depression.